Clip Health’s technology platform enables the best combination of accuracy, affordability, and consumer-friendly product design in the market.
Our technology is adaptable to detection of a variety of targets from a wide variety of sample types. We can detect or quantify bacteria, viruses, proteins, hormones, and small molecules from sample types including blood, urine, saliva, and swabs.
The Clip platform combines our proprietary glow-in-the-dark nanochemistry with signal processing artificial intelligence to enable high-performance affinity-based assays across different analyte types. We have shown >100-fold lower limits of detection vs. colorimetric lateral flow assays for bacterial pathogen detection.
Automated EHR/LIMS integrations at the point-of-care and public health reporting/telehealth for at-home self-testing are enabled by our app-connected, palm-fitting, reusable Clip Core device.
In addition to developing and commercializing our own products, we are a platform company in the true sense of the word “platform”. We’re building technology infrastructure across our chemistry, hardware, and software in a way that enables third parties to develop and commercialize applications for health screening, diagnostics and monitoring. If you work for an organization that wants the unique combination of high accuracy, low cost, and consumer compatibility, we’d love to talk to you. Clip Health has the proven in-house ability to take IVD products from concept all the way through FDA review, market launch, and high-volume manufacturing.
Here are early proof-of-concept peer-reviewed publications on Clip Health’s technology platform
- Persistent luminescence strontium aluminate nanoparticles as reporters in lateral flow assays, Analytical Chemistry 2014 Oct 7; 86(19):9481-8
- A low-cost smartphone-based platform for highly sensitive point-of-care testing with persistent luminescent phosphors, Lab on a Chip 2017 Mar 14; 17(6):1051-1059
- Evaluation of a nanophosphor lateral-flow assay for self-testing for herpes simplex virus type 2 seropositivity, PLOS ONE 14(12): e0225365
- An over-the-counter-friendly rapid immunoassay for Chlamydia trachomatis that approaches the clinical performance of FDA-cleared nucleic acid amplification tests, (in preparation)